Overview

GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection

Status:
Completed
Trial end date:
2011-01-18
Target enrollment:
Participant gender:
Summary
This study will determine the safety, tolerability and efficacy of GSK1322322 verses Linezolid in subjects with Acute Bacterial Skin and Skin Structure Infection (ABSSSI).
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Linezolid